Xeris Biopharma Holdings Inc (NASDAQ: XERS) on Friday, soared 2.66% from the previous trading day, before settling in for the closing price of $4.13. Within the past 52 weeks, XERS’s price has moved between $1.69 and $4.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 197.66% annually for the last half of the decade. The company achieved an average annual earnings per share of 77.32%. With a float of $142.31 million, this company’s outstanding shares have now reached $149.43 million.
In an organization with 394 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 83.86%, operating margin of -16.57%, and the pretax margin is -28.12%.
Xeris Biopharma Holdings Inc (XERS) Insider and Institutional Ownership
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Xeris Biopharma Holdings Inc is 7.55%, while institutional ownership is 43.38%. The most recent insider transaction that took place on Aug 12 ’24, was worth 10,147. In this transaction Director of this company bought 4,515 shares at a rate of $2.25, taking the stock ownership to the 25,200 shares. Before that another transaction happened on Aug 09 ’24, when Company’s Director bought 4,285 for $2.37, making the entire transaction worth $10,134. This insider now owns 20,685 shares in total.
Xeris Biopharma Holdings Inc (XERS) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.03 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 77.32% per share during the next fiscal year.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Trading Performance Indicators
Xeris Biopharma Holdings Inc (XERS) is currently performing well based on its current performance indicators. A quick ratio of 1.19 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.21.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.38, a number that is poised to hit -0.05 in the next quarter and is forecasted to reach 0.10 in one year’s time.
Technical Analysis of Xeris Biopharma Holdings Inc (XERS)
Let’s dig in a bit further. During the last 5-days, its volume was 4.14 million. That was better than the volume of 1.94 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 58.56%. Additionally, its Average True Range was 0.23.
During the past 100 days, Xeris Biopharma Holdings Inc’s (XERS) raw stochastic average was set at 84.92%, which indicates a significant increase from 72.34% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.11% in the past 14 days, which was higher than the 44.40% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.57, while its 200-day Moving Average is $2.95. However, in the short run, Xeris Biopharma Holdings Inc’s stock first resistance to watch stands at $4.41. Second resistance stands at $4.58. The third major resistance level sits at $4.76. If the price goes on to break the first support level at $4.06, it is likely to go to the next support level at $3.88. The third support level lies at $3.71 if the price breaches the second support level.
Xeris Biopharma Holdings Inc (NASDAQ: XERS) Key Stats
Market capitalization of the company is 652.71 million based on 149,081K outstanding shares. Right now, sales total 163,910 K and income totals -62,260 K. The company made 54,270 K in profit during its latest quarter, and -15,740 K in sales during its previous quarter.
